Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PLCB2
REST API REST API
Homo sapiens
PLCB2 is differentially expressed in 231 experiments: 107 organism parts: bone marrow, liver, ... (105 more);, 223 disease states: normal, acute myeloid leukemia, ... (221 more);, 87 cell types 193 cell lines 38 compound treatments and 72 other conditions.
Synonyms FLJ38135
Orthologs Plcb2 (Rattus norvegicus)   PLCB2 (Danio rerio)   PLCB2 (Gallus gallus)   Plcb2 (Mus musculus)   PLCB2 (Bos taurus)   PLC1 (Saccharomyces cerevisiae)   Plc21C (Drosophila melanogaster)   plcb2 (Xenopus laevis)   PLCB2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, Golgi apparatus, phospholipid binding, signal transducer activity, phospholipase C activity, synaptic transmission, lipid metabolic process, activation of phospholipase C activity, lipid catabolic process, phospholipid metabolic process, hydrolase activity, signal transduction, calcium ion binding, detection of chemical stimulus involved in sensory perception of bitter taste, sensory perception of bitter taste, intracellular signal transduction, phosphatidylinositol phospholipase C activity, G-protein beta/gamma-subunit complex binding, G-protein beta/gamma-subunit complex
InterPro Term PLC-beta, C2_Ca-dep, PLipase_C_PInositol-sp_X_dom, C2_membr_targeting, PLC-beta_C, PLipase_C_EF-hand-like, Pinositol_PLipase_C, PLipase_C_Pinositol-sp_Y
UniProt Accession B9EGH5, Q00722, Q59F77, Q9BVT6
Search EB-eye ENSG00000137841
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-GEOD-1577, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (27 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081
BT-474
2
2
E-GEOD-5823, E-GEOD-3529
PC3
2
E-GEOD-5258, E-MEXP-2034
SW962
1
E-MTAB-37
LNCaP
1
E-GEOD-14990
NCIH82
1
E-MTAB-37
187 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-66, E-GEOD-360, E-GEOD-20677, E-GEOD-13987, ... (43 experiments)

Factor Value U/D Experiments
memory B cell
2
E-MEXP-2360, E-TABM-702
1
2
E-TABM-145, E-TABM-130
CD105+ endothelial
2
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-5370, ... (49 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
meningitis infected
1
E-MTAB-62
non-small cell lung cancer
1
E-MTAB-62
peripheral T-cell lymphoma
1
E-GEOD-19067
217 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (23 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
anti-CD3 + anti-CD28
1
E-GEOD-7307
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
unknown
1
E-GEOD-7307
PGE2
1
E-MEXP-1230
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
32 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
93 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-21138, E-GEOD-19665

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-1446, E-GEOD-10315, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494

Processing time: 0.287 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM